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Abstract:  26 
Glioblastoma (GBM) is the most aggressive primary brain tumour in adults, with a poor 27 
prognosis, despite surgical resection combined with radio- and chemotherapy. The major 28 
clinical obstacles contributing to poor GBM prognosis are late diagnosis, diffuse infiltration, 29 
pseudo-palisading necrosis, microvascular proliferation and resistance to conventional 30 
therapy.  These challenges are further compounded by extensive inter- and intra-tumour 31 
heterogeneity and the dynamic plasticity of GBM cells. The complex heterogeneous nature of 32 
GBM cells is facilitated by the local inflammatory tumour microenvironment, which mostly 33 
induces tumour aggressiveness and drug resistance. An immunosuppressive tumour micro-34 
environment of GBM provides multiple pathways for tumour immune evasion. Infiltrating 35 
immune cells, mostly tumour-associated macrophages, comprise much of the non-neoplastic 36 
population in GBM. Further understanding of the immunological microenvironment of GBM 37 
is essential to make advances in the development of immunotherapeutics. Recently, whole-38 
genome sequencing, epigenomics and transcriptional profiling have significantly improved 39 
the prognostic and therapeutic outcomes of GBM patients. Here, we discuss these recent 40 
genomic advances, the role of innate and adaptive immune mechanisms, and the presence 41 
of an established immunosuppressive GBM microenvironment that suppresses and/or 42 

















Glioblastoma (GBM) is the most common primary brain tumour with an annual incidence of 58 
3.19 per 100,000 population (1). GBM is a Grade IV astrocytoma, characterised by 59 
uncontrolled cellular proliferation, local infiltration, extensive genomic instability, tendency 60 
for necrosis, angiogenesis, and resistance to therapy. Histopathologically, GBM is composed 61 
of a heterogeneous cell population, consisting of differentiated and undifferentiated tumour 62 
cells, along with differences in morphology and capacity for self-renewal and proliferation (2, 63 
3). Despite aggressive treatment including surgical resection and radiotherapy with 64 
concomitant chemotherapy, prognosis remains poor due to GBM recurrence, with a median 65 
survival of 14.6 months (4). In molecular terms, this poor prognosis is mostly characterised by 66 
deregulation of many key signalling pathways involving cell survival, growth, proliferation and 67 
apoptosis due to genomic mutations (5). GBM is a robust malignant tumour, distinguished by 68 
its local invasion pattern (6, 7). Generally, GBM do not metastasize extracranially; however 69 
there have been rare cases in which 0.44% of GBM have spread to other parts of the body 70 
usually when patients have undergone craniotomy (8, 9).  71 
GBM is highly invasive, lack clear margins, and therefore, pose a challenge for complete 72 
surgical resection and almost inevitably recur in patients who have been treated. Despite 73 
recent advances in genomics, chemotherapy, immunotherapy, and technological approaches 74 
to cancer models, the treatment outcome for GBM patients has remained consistently poor. 75 
Clinical symptoms vary and depend on size and location of tumour; it may include headache, 76 
nausea, dizziness, confusion, speech difficulties, and change in personality, new onset of 77 
seizures and focal neurological deficit. The tumour is generally located in the frontal and 78 
temporal lobes of the brain and can also rarely occur in the brainstem, cerebellum and spinal 79 
cord (10, 11). GBM is most often de novo i.e. primary GBM, which account for approximately 80 
90% of GBM cases and are predominately found in patients older than 45 years (5).  The 81 
remaining 10% of GBM cases develop from a lower-grade tumour progressing to a higher-82 
grade malignancy (secondary GBM) over a 5-10 year period, and is primarily present in 83 
patients younger than 45 years. These subtypes have distinct genetic aberrations but are 84 
histologically indistinguishable (5, 12, 13).  85 
Despite advances in our understanding of cancer biology, managing GBM remains a challenge. 86 
It is important to understand why treatment for GBM has largely been ineffective; it is mainly 87 
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due to the heterogeneous nature of the tumour microenvironment. It has not been possible 88 
to produce appropriate cancer models for GBM that would help us study the properties by 89 
which GBM is promoted and sustained. Therefore, it is vital to study the role of the immune 90 
system in the GBM microenvironment.  This review aims to analyse the recent genomic 91 
advances in dissecting the considerable molecular and cellular heterogeneity in GBM and the 92 
innate and adaptive immune mechanisms that are suppressed, which ultimately contribute 93 
towards tumorigenesis. 94 
GENOMIC LANDSCAPE OF THE GBM MICROENVIRONMENT 95 
GBM has considerable cellular and molecular heterogeneity, both between patients and 96 
within the tumour microenvironment itself. GBM subtyping via histological examinations is a 97 
poor prognostic indicator for gliomas. Glioma is an overarching term used for brain tumours 98 
of glial cells: astrocytes: glioblastoma; oligodendrocytes: oligodendroglioma; ependymal 99 
cells: ependymoma and was improved by combining histology with molecular genotyping of 100 
key markers (e.g. iso-citrate dehydrogenase (IDH), ATP-dependent helicase (ATRX), Lys-27-101 
Met mutations in histone 3 (H3K27M), p53 mutations, and 1p/19q chromosomal deletion 102 
(Louis et al., 2016; Bent, 2010). However, the era of genomics and next generation sequencing 103 
(NGS) has led to a greater understanding of the formation and pathogenesis of these tumours 104 
by identifying core molecular pathways affected, facilitating the design of novel treatment 105 
regimens.  The Cancer Genome Atlas (TCGA) network was among the first to conduct a major 106 
genomic study on cancer interrogating 33 different types, with particular emphasis on GBM, 107 
leading to the whole genome characterisation and molecular genotyping of 600 GBM and 516 108 
other low-grade gliomas (Wang et al. 2017). Novel genomic variations were identified, e.g. 109 
deletions of neurofibromin gene (NF1) and parkin RBR E3 ubiquitin protein ligase (PARK2) as 110 
well as copy number variations (CNVs) of AKT serine/threonine kinase 3 (AKT3) and other 111 
single nucleotide variations (SNVs). Furthermore, patients who had undergone treatment 112 
were shown to have higher genetic variability in their recurrent tumours than untreated 113 
patients, showing additional layers of complexity in the pathogenesis and progression of 114 
GBM. These data allowed the TCGA to characterise GBM into distinct molecular subtypes (14). 115 
Subsequent studies further refined this classification using additional genomic and 116 
transcriptomic data to give the following three most clinically relevant molecular subtypes of 117 
GBM: proneural (PN), mesenchymal (MSC) and classical (CL) (Table 1). This classification was 118 
5 
 
based on platelet-derived growth factor receptor A (PDGFRA) gene/IDH mutation, NF1 119 
mutation and epidermal growth factor receptor (EGFR) expression, respectively (15,16). EGFR 120 
is also an important marker for proliferation and MSC subtype (17). 121 
These GBM classifications have been key in trying to associate genomic/molecular variation 122 
to clinical phenotypes, particularly in recurrent episodes and treatment failures, such as the 123 
PN-MSC subtype-switch in the tumour aggressiveness and resistance. In line with this, a 124 
recent study (where glioma cells were treated with varying concentrations of cytokines) 125 
revealed that cytokine storm in the GBM tumour microenvironment enforces PN-subtype 126 
switch to MES-subtype by transcriptional networking and induces radiation-resistance 127 
properties (18). Similarly, another study shows that post-translational modification of 128 
oncogenic transcription factors (TF) such as OLIG2, switches the proliferative nature of glioma 129 
cells into a highly invasive phenotype by controlling the inflammatory cytokine, TGF-β (19). 130 
Prognostically, GBM patients with the MSC subtype tend to have a poor survival and 131 
resistance to therapy in comparison to other subtypes. Inevitably, NF1 drives mutations and 132 
a characteristic NF-κB transcriptome profile, an important inflammatory TF that seems to be 133 
very specific to MSC subtype-specificity (20). Moreover, NF1 is an RAS-GTPase and an 134 
important tumour suppressor gene. Its disruption, through mutation or deletion, is associated 135 
with enhanced tumour aggression and invasiveness (21). Deficiency in NF1 is also key in 136 
macrophage/microglia recruitment (22-24). 137 
Most of the early TCGA studies have utilised tissue from one single random location in the 138 
tumour, but as mentioned above, GBM has high levels of cellular heterogeneity, with several 139 
factors affecting the molecular subtype, including anatomical location. Using RNA-Seq, a 140 
single GBM sample was shown to contain cells from 3 different subtypes (25). Approximately 141 
8% of the GBM samples contain more than one subtype.  Therefore, there needs to be a 142 
refinement of these genomic approaches to characterise genetic and protein changes to both 143 
single cell and specific cell populations within the tumour (26). Understanding the nature and 144 
consequences of cellular and molecular heterogeneity in GBM is crucial in identifying new 145 
biomarkers and therapeutic interventions. To date, there has been little evidence of 146 
significant association between molecular subtype and prognosis, although recently poorer 147 
prognosis has been observed in the MSC subtype, compared to other subtypes (20). 148 
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Furthermore, enhanced survival was observed in GBM samples of low heterogeneity, in 20% 149 
of the total GBM samples analysed (16). 150 
Further sub-classification and refinement of subtypes has also required an epigenetic 151 
approach. In gliomas, the mutational status of IDH is an important marker, and interestingly, 152 
gliomas with mutated IDH also have a particular cytosine-phosphate-guanine (CpG) island 153 
methylator phenotype (G-CIMP). The G-CIMP of DNA methylation seems to identify a distinct 154 
subgroup of glioma, with G-CIMP ‘high’ subgroup of tumours in younger patients at diagnosis 155 
that having better overall prognosis. The G-CIMP ‘high’ phenotype is also more commonly 156 
observed in lower-grade gliomas than GBM and tends to have the PN molecular subtype (27, 157 
28). Furthermore, in patients treated with temozolomide (TMZ), those that had recurrences 158 
and had lost methylation of the O(6)-methylguanine-DNA methyl transferase (MGMT) 159 
promoter, had increased genetic mutations compared to untreated patients, indicating that 160 
this methylation phenotype could contribute to the chemotherapeutic resistance of the 161 
tumour (27, 28). However, MGMT methylation status is also predictive of treatment response 162 
in IDH wild-type GBM patients (29) and abnormal methylation of MGMT has increased 163 
prognosis in some GBM patients after TMZ treatment (30). Recently, small non-coding RNA 164 
molecules (ncRNAs or miRNAs) have been suggested to be involved in a number of cancers. 165 
Five miRNAs were found to be involved in MGMT alterations and tumour suppressor 166 
functions of TP53 (miR-21, miR-125b, miR-34a, miR-181d, and miR-648) in GBM progression 167 
(31). In particular, miR-21 and miR-181d were associated with GBM tumorigenesis (32-35), as 168 
have a number of other miRNAs, miR-144 and miR-29a (36-38). These miRNAs may prove to 169 
be important biomarkers for GBM, but their specificity needs to be further validated. 170 
IDH mutation has been linked with chromosomal abnormalities and prognosis in low-grade 171 
gliomas. Correlations have been observed in 3 subtypes: IDH mutant with 1p/19q co-deletion 172 
correlating to increase survival (39, 40), whilst IDH mutant without 1p/19q co-deletion and 173 
IDH wild-type was correlated with poor prognosis that is similar to GBM (14). Furthermore, in 174 
patients with oligodendroglioma (which often contain the 1p/19q deletion), they tended to 175 
respond better to chemo- and radiotherapy, with an enhanced prognosis overall (41, 42). 176 
EGFR-TACC fusion via a chromosomal translocation has been described in a small number of 177 
GBM patients, but its clinical significance is unclear (26), but may have strong sensitivity to 178 
some tyrosine kinase inhibitors (43). 179 
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Further studies have identified known oncogenic pathways in GBM such as RB, p53, 180 
RTK/RAS/P13K (14); a putative attempt at linking GBM molecular subtypes to cell types of the 181 
central nervous system has also been suggested based on gene expression signature: PN 182 
subtype - oligondendrocytic, CL subtype-astrocytic and MSC subtype–astrocytic (cultured 183 
cells) (15,44). This remains to be fully substantiated.  However, the MSC subtype generally is 184 
the most heterogeneous, showing its complexity compared to other non-MSC tumours (15). 185 
A few studies have also reported a switch between molecular subtypes in recurrent tumours 186 
that may be driven by the accumulation of new genetic mutations (17, 45, 46). It has been 187 
suggested that recurrent tumours may acquire extra mutations and evolve along two distinct 188 
molecular pathways governed by p53 mutation (Type 1 GBM) or EGFR amplification (Type 2 189 
GBM) (45).  Although the MSC subtype is the most common subtype in GBM, the shift from 190 
PN to MSC has not been clearly shown to occur (16). 191 
Comparative studies between initial and recurrent GBM have been conducted using specific 192 
known markers and genome-wide analysis to further understand tumorigenesis and 193 
progression. Immunohistochemistry has been used to study proteins thought to be involved 194 
in DNA repair and tumour growth such as MutL homolog 1 (MLH1), MutS homolog2 (MSH2) 195 
and tumour suppressor protein p53 (47). These were found to be expressed significantly 196 
lower in recurrent GBM. Furthermore, reduction of MLH1 and post-meiotic segregation 197 
increased 2 (PMS2) proteins conferred TMZ resistance and is associated with recurrent TMZ 198 
(48). Genomic, transcriptomic and epigenetic approaches have been utilised in a number of 199 
longitudinal studies using whole epigenome sequencing (WES), targeted genome sequencing 200 
(TES), loss of heterozygosity (LOS), quantitative PCR, RNA-Seq, transcriptome profiling and 201 
whole genome sequencing (WGS). These studies have identified numerous additional 202 
pathways, biomarkers and deciphered the mutational behaviour of the tumour with and 203 
without treatment. Genetic differences in tumour evolution were observed in primary and 204 
recurrent tumours, sharing relatively few initial mutations (49). Subtype switching was also 205 
found to be common (66%) in primary GBM and may be a result of accumulation of additional 206 
mutations in highly expressed genes (50). A new mutation in latent TGF-β-binding protein 4 207 
(LTBP4) gene was found in 10% of recurrent GBM, whilst the TGF-β pathway was also found 208 
to be involved in tumour pathogenesis (50). Primary GBM tumours without p53 and EGFR 209 
mutations gain novel EGFR amplification during recurrence and can follow two distinct 210 
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pathways, depending on the genetic type of the original tumour (45).  In another study, using 211 
WES, considerable tumour heterogeneity, mediated by EGRF overexpression was observed in 212 
GBM, as well as a deletion on chromosome 10, losing phosphatase and tensin homolog (PTEN) 213 
and cyclin-dependant kinase inhibitor 2A (CDKN2A) genes (51). A further study analysed the 214 
evolution of mutations in GBM by using paired samples and found that 67.9% were clonal in 215 
nature, whilst 29.8% were sub-clonal (52). Of these, 90% of p53 and PIK3CA/PIK3R1 mutations 216 
were also clonal, suggesting that the nature of p53 mutations in GBM has implications for 217 
tumorigenesis (52). TMZ treatment also influences the nature and rate of mutations in 218 
recurrent GBM tumours (53). Transcriptomic profiling revealed that a macrophage/microglia-219 
rich tumour microenvironment is key for the development of the MSC molecular subtype, 220 
which is further facilitated by NF1 depletion (16). 221 
Epigenomic analysis has offered important insights into molecular mechanisms, such as 222 
methylation, underpinning clinical phenotypes.  Promoter methylation of the DNA-repair 223 
gene MGMT results in gene silencing which was associated with significantly better prognosis 224 
in patients treated with TMZ, than those that did not have a methylated MGMT promoter 225 
(54). In this study, 45% of 206 GBM cases were found to have MGMT promoter methylation 226 
(54). In a recent study, a comprehensive DNA methylation analysis of 200 tumours from 77 227 
GBM patients identified biomarkers which, at the time of diagnosis, were found to be 228 
predictive of GBM recurrence and prognosis. Patients in the G-CIMP ‘high’ subgroup, with IDH 229 
mutation and intact 1p19q were found to have a good clinical outcome upon recurrence 230 
compared to patients with altered and lowered methylation (G-CIMP ‘low’), at the time of 231 
diagnosis, with the latter having an increased risk of recurrence and significantly poorer 232 
clinical outcome (55). Another important recent study conducted a detailed survey of DNA 233 
methylation in GBM tumours using the reduced representation bisulfite sequencing (RRBS) 234 
technique and RNA-Seq, and made significantly findings in dissecting out tumour 235 
heterogeneity based on DNA methylation profile (56). Transcriptional subtypes of tumour 236 
were identified as well as DNA methylation profiles, predictive of immune cell infiltration, 237 
necrosis and tumour cell morphology. Furthermore, de-methylation of Wnt signalling 238 
promoters upon recurrence and progression was also associated with worse clinical outcome 239 
(56).  240 
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These promising studies showing genomic variations, transcriptional profiles, molecular 241 
abnormalities of G-CIMP and other global DNA methylation profiles, along with the changes 242 
in the local tumour microenvironment, will lead to a greater understanding of the complex 243 
tumour-immune heterogeneity, and enable interventions to prevent GBM tumorigenesis and 244 
progression in the future. One such key player is the complement system, the most potent 245 
and versatile humoral innate immune system. 246 
COMPLEMENT SYSTEM AND GBM 247 
The complement system is one of the first lines of defence of innate immunity in the brain 248 
and is comprised of more than 30 different glycoproteins which are soluble proteins, cell 249 
associated regulators or receptors (57). Complement can be activated by pathogens and 250 
altered-self cells or indirectly by pathogen-bound antibodies. Activation of complement 251 
opsonises target pathogens or altered-self cells for phagocytic uptake, inducing an 252 
inflammatory response and enabling cell lysis. Complement is activated through 3 different 253 
pathways which are the Alternative, Classical and Lectin pathways (Figure 1) (58). All activated 254 
pathways result in covalent attachment of C3b to the target cell, where each pathway can 255 
finally assemble pores in the lipid bilayer of the cell under attack and cause cell lysis (59). The 256 
alternative pathway is auto-activated by a process termed ‘tick-over’, where C3 (the most 257 
abundant complement protein) is spontaneously hydrolysed, designated C3(H2O). 258 
Complement protein Factor B associates with C3(H2O) and in-turn is cleaved by Factor D 259 
generating Ba and Bb. The larger cleaved product Bb remains associated and forms the 260 
protease complex C3(H2O)Bb which cleaves additional C3 to form the cleaved products C3a 261 
and C3b. The cleaved anaphylatoxin C3a can elicit inflammation whereas C3b can bind to and 262 
opsonise pathogens and also bind to C3 convertase (C3bBb) to form C5 convertase 263 
(C3bBbC3b). An amplification loop can also be initiated when C3b generated from the 264 
Classical and Lectin pathway bind with Factor B from the alternative pathway allowing Factor 265 
D to cleave it similarly to ‘tick-over’ (59,60). The activation of the Classical pathway is through 266 
the binding of C1q directly to pathogens, altered-self cells or to antibody antigen complexes. 267 
This triggers the C1r to activate C1s which cleaves C4 and C2 to generate C4a anaphylatoxin, 268 
C4b opsonin, C2a and C2b. C4b and C2b bind to form C3 convertase (C4b2b) (61). Similarly, in 269 
the Lectin pathway both C4 and C2 are also cleaved producing the same products that 270 
generate C3 convertase (C4b2b). The lectin pathway is activated by mannose binding lectin 271 
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(MBL) binding to oligosaccharides on pathogens. The associated enzyme mannan-binding 272 
lectin serine protease (MASP) 1 and 2 are responsible for the cleavage of C4 and C2 (62, 63). 273 
All 3 pathways converge at C3 convertase enabling the cleavage of the central complement 274 
component C3 to form C3a and C3b. The opsonin C3b binds to C3 convertase and generate 275 
C5 convertase (C3bBbC3b) (C4b2Bc3b), which enables the cleavage of C5 to form 276 
anaphylatoxin C5a, and opsonin C5b. C5b binds to the pathogen and also to C6, C7, C8, and 277 
C9, to produce a membrane attack complex (MAC) which generates pores through the 278 
pathogen’s cell membrane, leading its destruction by osmotic cell lysis (57). 279 
The complement system plays an important role in defence against pathogens, angiogenesis, 280 
neuroinflammation and neurodegeneration, as well as regulation of adaptive immunity. Apart 281 
from these functions, complement system also has a key role to play in cancer 282 
immunotherapy, cytotoxicity and tumorigenesis (64). Over the years, studies have shown that 283 
GBM is resistant to complement-mediated killing and this is facilitated by membrane-bound 284 
and soluble complement inhibitors. These regulators include Factor H (FH), FH-like protein 1 285 
(FHL-1), C1 inactivator (C1-IA), protectin (CD59), membrane co-factor protein (CD46) and 286 
decay accelerating factor (CD55) (65-67). FH is an important soluble regulator of the 287 
Alternative pathway, as it competes with factor B for C3b binding, to prevent the formation 288 
of C3 convertases and thus accelerates the decay of C3 convertase (C3bBb) to dissemble the 289 
enzyme (Figure 1). FH also acts as a co-factor for factor I to inactivate C3b by cleaving the α-290 
C3b chain into 2 fragments (68, 69). FH is composed of 20 complement control proteins (CCPs) 291 
of which CCPS 1-4 facilitate the functional activity of FH. FHL-1 represents the truncated form 292 
of FH as its 7 CCPs are identical to the N-terminal of FH, and therefore elicit the same 293 
inhibitory ability (69, 70). In the presence of glycosaminoglycans and sialic acid, which are 294 
present on self-cells, the affinity of FH increases for surface bound C3b via the 3 binding sites 295 
at CCPs 1-4, 7-15, and 19-20. The polyanions are only present on self-cells, thus enabling FH 296 
to differentiate between self and nonself-cells (68, 71). 297 
 298 
Complement regulators 299 
Complement regulatory proteins are important in protecting healthy self-cells from 300 
complement attack by exerting tight regulatory functions. Regulation is required at all major 301 
checkpoints of complement activation and amplification to prevent a deleterious effect on 302 
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self-cells from an over-reactive complement system. Healthy cells express soluble regulators 303 
such as FH and membrane bound regulators including CD59, CD55 and CD46 (Table 2), which 304 
all use different mechanisms to provide protection (72, 73). Soluble regulators inactivate 305 
complement as they are attracted to self-structure over foreign surfaces (74, 75). However, 306 
soluble and membrane-bound complement regulators can act as double-edged swords by 307 
overregulating the complement system to the point it is unable to eliminate tumour cells. 308 
Studies suggests that the expression of complement regulators by tumours including GBM 309 
allows these cells to proliferate unchecked. This highlights the significance that complement 310 
regulators play in the tumour cells’ avoidance of complement attack. As knowledge of the 311 
relationship between complement regulatory proteins and tumours evolve, it is possible that 312 
their therapeutic blockade can have an important role in tumour treatment (76, 77).  313 
 314 
Factor H 315 
Factor H is secreted by GBM cell lines such as H2, U138, U118 and U87 (78). In another study 316 
by Junnikkala et al., expression of RNA and protein production of FHL-1 in the malignant cells 317 
was found to exceed that of FH, in contrast to normal serum where the concentration of FH 318 
is greater than FHL-1 (66) (Table 2). It appears that endogenously synthesised and fluid phase 319 
FH and FHL-1 from plasma can successfully bind to the GBM cell membrane, efficiently 320 
regulating complement activation and promoting the cleavage of membrane deposited C3b 321 
into its inactive form iC3b. Ultimately, this mechanism prevents activation of the late stages 322 
of complement activity, to elicit cell lysis via MAC formation because there is reduced C5b-9 323 
deposition. The inhibitory effect of secreted FH and FHL-1 can be overcome through 324 
neutralisation of FH and FHL-1 with antibodies that target the C3b binding site and by the 325 
removal of sialic acid to sensitise GBM cells to complement lysis.  FH and FHL-1 play a crucial 326 
role in GBM tumorigenesis by enabling the acquisition of GBM cells’ exceptional resistance to 327 
complement mediated killing (66). In a more recent study on primary tumour cells derived 328 
from 3 GBM patients, secretion of complement Factor H related protein 5 (FHR5) was also 329 
reported (79). It was found that the cells secreted FHR5, but not FH, and that FHR5 inhibited 330 





Complement 1 inactivator A 334 
GBM resistance to complement-mediated lysis can be acquired by the production of 335 
Complement 1 inactivator (C1-IA) or C1 inhibitor (C1-inh) (Table 2). C1-IA, a serine protease, 336 
is able to regulate classical pathway activation by irreversibly binding to C1r and C1s 337 
proteases, which along with C1q, form the multiprotein complex C1, which is the first 338 
component in the initiation of the classical pathway (80, 81). The ability of C1-Inh to bind to 339 
C1r and C1s protease subsequently prevents C1r autoactivation and C1s activation, which in 340 
turn, prevents the cleavage of C4 and C2. This ultimately stops the formation of the Classical 341 
pathway’s C3 convertase (C4b2a) (82). Gene expression and mRNA analysis in human GBM 342 
tissues showed an upregulation of C1-inh, a potent inhibitor of the classical pathway (65). 343 
Inhibition of C1-inh in rats with GBM, using appropriate antibodies, was found to increase 344 
survival but also led to decreased levels of cytokines IL-1β and GM-CSF, which are associated 345 
with an immunosuppressive tumour microenvironment (65, 83). 346 
Membrane-bound complement regulators 347 
The ability of GBM cells to avoid complement attack is not only determined by soluble 348 
inhibitors but also by membrane bound regulators such as CD59, CD55 and CD46 (76, 77) 349 
(Table 2). CD59 is a major protective element against complement mediated lysis. It binds to 350 
C5b-8 complex and blocks the sites to which C9 can attach, thus, preventing the insertion and 351 
polymerisation of C9. As a result, the final step of MAC assembly on the cell membrane is 352 
prevented (84). CD55 is an anchored membrane regulator that inhibits the formation and 353 
accelerates the decay of C3 and C5 convertase of the alternative and classical pathway to 354 
prevent complement activation (85). The complement cascade is also regulated by CD46, 355 
which serves as a co-factor of factor I inactivation of C3b and C4b, deposited on the 356 
membrane (86).   357 
CD59 is considered one of the most important membrane regulators. In a study by Maenpaa 358 
et al., it was shown that CD59 was expressed in 14 human glioma tissues as well as 7 glioma 359 
cell lines (67). In normal astrocytes, the expression of CD59 is weak as the need to protect 360 
these cells from complement is reduced due to the blood-brain barrier, which restricts entry 361 
of many pathogens into the brain (77). Successful binding of CD59 to C5b-8 complex inhibits 362 
the formation of MAC at the point of insertion of C9 into GBM cell membrane, thus protecting 363 
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the cell from complement mediated killing (66). The inhibition of CD59 by neutralising 364 
antibodies enables the cells to overcome the resistance of GBM to complement mediated 365 
cytolysis (66). In the same study, CD55 and CD46 were also shown to be moderately expressed 366 
in GBM cell lines, and neutralising them with respective antibodies showed moderate 367 
complement-mediated cytolysis, although CD59 was considered to be the most important 368 
complement regulator on GBM cells (66). 369 
Role of microglia and macrophages in GBM 370 
The central nervous system (CNS) had historically been considered an immune privileged site. 371 
This is primarily because it lacks a traditional lymphatic system, containing only a few antigen 372 
presenting cells which would mount an extremely weak immune response (87). Considering 373 
recent data, the characteristics of immune privilege have been redefined and are no longer 374 
considered absolute (87). The concept of immune privilege had stemmed from the ability of 375 
antigens within the brain to avoid systemic immunological recognition (88). It is now evident 376 
that immune privilege is specific to brain parenchyma which is imperative for damage 377 
limitation during inflammation. The brain parenchyma is an extremely sensitive part of the 378 
organ with poor regenerative capacity and is protected by the blood brain barrier, a semi-379 
permeable membrane consisting of endothelial cells that separate the blood from the 380 
cerebrospinal (88). 381 
The CNS is able to coordinate a robust immune response involving both the innate and 382 
adaptive immune systems (89). During inflammation immune cells are able to migrate to 383 
perivascular spaces following chemotaxis (90). Studies have shown that antigens can enter 384 
the cervical lymph nodes by passing through the Virchow Robin Perivascular Space within the 385 
walls of the cerebral arteries (91). It is also possible for immunoglobulins to cross the blood-386 
brain barrier via carrier mediated transporters by attaching to FcRn receptor (92). Antigen 387 
presentation occurs as dendritic cells can travel outside of the brain and present antigens to 388 
T-cells located in the cervical lymph nodes (93). However, inflammation and disease in the 389 
CNS can compromise the integrity of the blood-brain barrier, thereby enabling circulating 390 
immune cells to migrate past the it and infiltrate the parenchyma (94). 391 
Microglia are the resident macrophage of the CNS comprising 5-20% of the total glial cell 392 
population. In the brain, microglia are an important immune cell involved in immune 393 
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surveillance and are a crucial component of the first line of defence provided by innate 394 
immunity (95). Originally discovered over a century ago by Pio Del Rio Hortega, it is now clear 395 
that resident microglia originate from haematopoietic precursor cells of immature yolk sac 396 
during early embryogenesis (96). Microglia are usually found in a ‘resting’ state, although it 397 
means that the shape of microglia is such that there are branched extensions or processes 398 
that actively patrol and perform surveillance of local areas. Upon receipt of inflammatory 399 
stimuli, circulating microglia change into ‘amoeboid’ shape, and additional recruitment of 400 
macrophage from infiltrating circulating monocytes takes place (97, 98). Apart from 401 
surveillance, microglia actively contribute to brain development and CNS homeostasis by 402 
apoptotic cell removal, maintenance and pruning of synapses, and regulation of neuronal 403 
activity (98, 99). In GBM, a second group of macrophages derived from peripheral bone 404 
marrow, are present (100). In the brain, macrophages are restricted to the perivascular, 405 
choroid and meningeal locations. However, disruption to the blood-brain barrier by disease 406 
or inflammation allows macrophage to gain entry to the parenchyma (101). These 407 
mononuclear cells are difficult to differentiate from microglia as they intermingle in GBM 408 
(102).  409 
Traditional approaches to distinguish macrophage and microglia involved CD45 antibody as 410 
microglia are defined as CD45low, whereas macrophages were defined as CD45high (102,103). 411 
Despite this, it is still unclear as to whether microglia or macrophage make up most of the 412 
mononuclear density in GBM. Parney et al. suggested that gliomas contained more recruited 413 
macrophages than resident microglia (104). However, Muller et al. challenged this concept as 414 
they demonstrated resident microglia were the main source of mononuclear cells in gliomas 415 
and that the microglia present had increased their expression of CD45 (105). Together, 416 
microglia and macrophages in GBM are generally referred to as tumour-associated 417 
macrophages (TAM) (Figure 3) (106). 418 
It has also been reported that in the MES subtype, deficiency of NF1 leads to increased 419 
infiltration of TAM (16). This may explain why GBM subtype-specific cell autonomous 420 
functions drive tumour aggressiveness and therapy resistance and have poorer prognosis. 421 
Furthermore, this study also highlighted that the tumour microenvironment in recurrent GBM 422 
showed the presence of more resident microglia/macrophages as compared to peripherally-423 
derived monocytes, indicating that treatment (such as radiotherapy) may have an impact on 424 
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monocytes, and thus in recurrent GBM, more efforts need to be made to address resident 425 
cells in the brain. This elegant study also showed increased CD8+ T cells in TMZ-induced 426 
hypermutated recurrent GBM (16).     427 
Microglial cells have been known to enhance infiltration leading to increased invasiveness of 428 
the tumour. A murine microglial cell study on mouse glioma cells found that tumour cell 429 
migration occurred sooner and was higher when compared to tumour cells without microglia 430 
(107). Another study using murine brain slices found that microglial cells stimulated the 431 
extracellular matrix metalloprotease (MMP)-2, which led to increased invasiveness of the 432 
tumour (108). Pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α, secreted by 433 
microglia, have been shown to increase tumour invasiveness in vitro (109). By specifically 434 
targeting microglia, using propentofylline which blocks secretion of IL-1β, IL-6 and TNF-α, 435 
tumour growth was found to regress (110).  436 
GBM cells secrete a range of chemo-attractants such as CCL2, CXCL12 and SDF-1, which 437 
actively recruit microglia and macrophages (111,112). Various CC and CXC chemokines are 438 
secreted including CCL2, CXCL12 and their receptors (113,114). CCL2 is one of the most 439 
important CC chemokines commonly expressed by GBM as it plays a key role in regulating the 440 
penetrative migration of TAM to the GBM microenvironment (115). It was the first TAM 441 
chemo-attractant identified in GBM; the extent of CCL2 expression is associated with glioma 442 
grade (116). CCL2 is highly expressed in GBM at mRNA and protein levels, thus contributing 443 
to a high influx of TAM (117).  Inhibiting CCL2 activity in mice studies (GL261 glioma and 444 
xenograft of human U87 models) with relevant antibodies has been shown to reduce 445 
infiltration and ultimately prolong survival (118). The receptor for CCL2 is CCR2 which are also 446 
present on microglia (119). In addition, microglia from the GBM tumour microenvironment 447 
have the capacity to secrete CCL2, thereby stimulating more microglia recruitment to the 448 
tumour (114). 449 
CXCL12, also known as stromal derived factor 1 (SDF-1), a chemokine, promotes TAM 450 
recruitment in high-grade gliomas. A murine high-grade model, ALTS1C1, demonstrated the 451 
chemo-attractant ability of SDF-1 for microglia and macrophages. High expression of SDF-1 452 
promoted the accumulation of TAM to areas of hypoxia in brain and tumour invasion (120). 453 
GBM cells also express colony stimulating factor-1 (CSF-1) which functions as TAM chemo-454 
attractant (121,122). CSF-1 is overexpressed in GBM, thus contributing to the high influx of 455 
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microglia/macrophages, promoting tumour invasion (121,122). High glucose has been shown 456 
to increase proliferation and inhibit apoptosis in a study on human GBM U87 cell line, by 457 
upregulation of vascular endothelial growth factor (VEGF) and is mediated by increased 458 
expression of chemotactic receptors including EGFR (123). A recent murine study showed that 459 
osteopontin is an important chemokine that attracts TAM to the GBM site, via integrin αvβ5 460 
(124). Further, αvβ5 deficiency was found to lead to a direct CD8+ T cell cytotoxic effect at the 461 
tumour site (124). 462 
Majority of newly recruited TAMs acquire an alternatively activated M2 phenotype under the 463 
direct influence of tumour cells to produce a pro-tumour microenvironment. M2 polarised 464 
TAMs produce mediators that contribute to the immunosuppressive microenvironment 465 
established by the tumour cells (125). TAMs are known to secrete anti-inflammatory 466 
cytokines such as IL-6, IL-10 and TGF-β, thereby enhancing immunosuppression in tumour 467 
microenvironment, leading to promotion of GBM cell growth and angiogenesis (126). Studies 468 
have shown that these anti-inflammatory cytokines supress M1 phenotypes as TGF-β inhibits 469 
pro-inflammatory cytokine expression and microglia proliferation whilst IL-10 polarises 470 
microglia to a M2 phenotype (127). TAMs are also known to express Fas ligand (FasL) which 471 
act as an immunosuppressant in GBM, as it contributes to the reduced presence of tumour 472 
infiltrating leukocytes (128).  473 
The pro-tumour microenvironment of GBM is supported by the expression of MMPs by TAM, 474 
including MMP-2 and MMP-9, which are involved in tumour growth by having an impact on 475 
angiogenesis, apoptosis and cell proliferation (129). Subsequent inhibition of MMPs derived 476 
from TAM have shown a reduction in tumour growth and angiogenesis (130,131). A study has 477 
shown that membrane type 1 (MT1) MMP is enhanced in TAM, which in turn, activates MMP-478 
2 in GBM, via microglial cells, thus increasing tumour invasion (132). TGF-β1 derived from 479 
microglia in GBM plays an important role in TAM-mediated promotion of tumorigenesis (133). 480 
It has been shown that TGF-β1, released by TAM, induces EMT and enhanced invasion of 481 
CD133+ GSCs which led to a pro-tumorigenic environment (134). Moreover, TAMs also 482 
contribute to tumorigenesis in GBM by providing proliferation promoting factors such as 483 
epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) (121). 484 
IL-10 from TAM in GBM have the ability to promote tumour growth in vitro via JAK2/STAT3 485 
pathway (135). Activation of STAT3 co-ordinates the expression of immunosuppressive 486 
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molecules by decreasing expression of major histocompatibility complex (MHC) class II and 487 
co-stimulatory molecule, CD40 (136). An activation loop is formed as the stimulation of STAT3 488 
by IL-10 enables activation of this transcription factor in nearby immune cells (136).  These 489 
cells include macrophage, natural killer (NK) cells and dendritic cells. As a result, the anti-490 
tumour activity of these immune cells is supressed (137). IL-10 derived by TAM also supresses 491 
MHC class II expression on monocytes and down-regulates the production of IFN-γ and TNF-492 
α in GBM, thus preventing anti-tumour activity (138). The overall effect of IL-10, secreted by 493 
TAM, on GBM, is immunosuppression which ultimately promotes a pro-tumour milieu (139).  494 
Dendritic cells (DCs) are antigen-presenting cells, involved in surveillance against pathogens 495 
and tumorigenic cells, and present these to T-cells, thereby serving as an important link 496 
between innate and adaptive immunity. This is utilised in anti-tumour therapies, to help 497 
induce a cytotoxic response against the tumour cells. In GBM, DCs are considered to present 498 
tumour cell peptides, leading to cytotoxic T cells response, and secretion of pro-inflammatory 499 
cytokines. Pre-clinical studies on murine glioma models have found DCs to be effective in 500 
inducing an effective tumour-response and increasing survival (140,141). Phase I clinical trials 501 
have found DC vaccination therapy to be safe and to elicit cytotoxic T cell responses (142,143). 502 
Early results from a subsequent Phase III clinical trial involving an autologous tumour-lysate 503 
pulsed DC vaccine was shown to be feasible and safe and may extend survival in GMB (144).  504 
Microglia in GBM are a major source of TGF-β, which plays a key role in contributing to the 505 
immunosuppressive GBM microenvironment (145). TGF-β enhances immunosuppression in 506 
GBM through a range of mechanisms including blocking T-cell activation and proliferation, 507 
inhibiting the activation of NK cells, down regulating IL-2 production, and promoting Tregs 508 
(146). Blocking T-cell activation can be achieved by the ability of TGF-β2 to supress HLA-DR 509 
antigen expression which is essential for tumour associated antigen presentation to CD4+ T-510 
cells (147). TGF-β is also capable of facilitating immune escape by inhibiting NKG2D (an 511 
activating receptor responsible for host-response to pathogen and tumour cells) on CD8+ T 512 
cells and NK cells ultimately rendering the cells less effective at cytotoxic destruction of GBM 513 
(148). Strategies which inhibit TGF-β expression can restore anti-tumour immunity in GBM. 514 
Transient silencing of TGF-β, using siRNA has been shown to prevent NKG2D expression and 515 
increase GBM susceptibility to destruction by immune cells (149). Murine glioma models have 516 
also shown that blocking TGF-β1 receptor increased the number of long-term survivors by 517 
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33% as opposed to the 6% observed in the control group. The level of CD8+ T cells were also 518 
increased, demonstrating a reversal of the immunosuppressive effect when TGF-β1 is 519 
inhibited (150).  520 
NK cells are a type of cytotoxic lymphocyte, which are known for its anti-viral and anti-tumour 521 
response, and secrete cytokines such as interferon-γ and TNF-α. Pre-clinical models of GBM 522 
have shown NK cells to be effective in HLA class I-mediated tumour lysis (151); IL-2 activated 523 
NK cells’ ability to kill GBM cells (152), and NK cells’ effectiveness in preventing metastasis in 524 
the GBM xenograft mouse model (153).   525 
ADAPTIVE IMMUNITY AND Treg CELLS 526 
Treg cells play a major role in mediating immune suppression of anti-tumour immune cells. In 527 
non-tumorigenic environments, Tregs usually are involved in preventing autoimmunity during 528 
an immune response (154). Tregs are a sub-population of CD4+ T-cells and can be categorised 529 
into two groups based upon their developmental origin. Thymus derived Tregs develop after 530 
antigen presentation by thymic epithelial cells and are characterised by high level expression 531 
of the transcription factor Forkhead Fox P3 (FoxP3) (155). By contrast, peripherally induced 532 
Tregs differentiate in the periphery upon antigen presentation and recognition by naive 533 
conventional CD4+ T-cells. IL-10 and TGF-β signalling are key contributors in supporting the 534 
induction of peripherally induced Tregs which have negligible FoxP3 expression (156). Studies 535 
have shown that there is a high influx of Tregs predominately of thymus origin, accounting for 536 
25% of tumour infiltrating lymphocytes. (157,158). The abundance of Tregs is associated with 537 
poor prognosis, as they shift the tumour cytokine milieu towards immunosuppression, 538 
preventing immune destruction of tumour cells (159). This enhanced immunosuppression is 539 
achieved by Tregs ability to restrict the function of infiltrating T cells by preventing production 540 
of IL-12 (160). The high influx of Tregs in GBM is likely due to CCL22 and CCL2 secreted by GBM, 541 
as they bind to CCR4 commonly expressed by Tregs (161,162).  542 
Immune checkpoint 543 
Immune checkpoints are co-stimulatory and co-inhibitory pathways that restrict the function 544 
of the immune system. These regulatory pathways supress T-cell activation and proliferation 545 
ensuring that immune responses are limited to maintaining self-tolerance which prevents the 546 
immune system attacking self-cells (163). An immune checkpoint involved in GBM immune 547 
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evasion is programmed cell death protein 1 ligand (PD-L1), which is a transmembrane 548 
glycoprotein of the B7 family co-stimulatory molecules (164). PD-L1 is not usually expressed 549 
in the CNS, therefore, its presence in this location is associated with a pathological or 550 
tumorigenic environment (165). PD-L1 is activated by binding to the receptor programmed 551 
cell death protein 1 (PD-1) to exert its inhibitory effect (166). In GBM, activation of PD-L1 552 
suppresses the proliferation and function of tumour derived cytotoxic T-cells, which would 553 
otherwise destroy the tumour cells. PD-L1 can also enhance Treg activity which will promote a 554 
pro-tumorigenic microenvironment (166) (Figure 3). 555 
Various immune cells express PD-L1 in GBM, such as CD4+ and CD8+ T cells (167). TAM express 556 
PD-L1 on their surfaces, whilst promoting PD-L1 expression on GBM cells (164). Genetic 557 
alterations have also been shown to contribute to PD-L1 expression as the loss of PTEN 558 
tumour suppressor gene enhances the expression of PD-L1 on glioma cells (168). The 559 
expression pattern of PD-L1 is positively correlated with glioma grade and is also associated 560 
with poor survival of GBM patients (167). A study in mouse glioma cell-line has shown that 561 
inhibiting PD-L1 with antibodies on glioma cells in combination with radiotherapy has clear 562 
survival benefits (169). PD-L1 expression was found to be dependent on IL-6; inhibition of IL-563 
6 signalling diminished expression of PD-L1, leading to increased survival and reduced tumour 564 
growth in orthotopic murine glioma model (170). 565 
Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) is another immune checkpoint molecule which 566 
plays a role in GBM immune evasion, as it modulates the early stages of T lymphocyte 567 
activation. CTLA-4 is expressed on activated T-cell and T-regs in a tumour microenvironment 568 
(171). Targeting CTLA-4 in glioma models with anti CTLA-4 antibodies proved useful in 569 
reversing immune evasion. This study showed an increase in long term survival, increased 570 
resistance to Treg mediated suppression and enhanced proliferation of CD4+CD25- T-cells 571 
(171). 572 
Despite several biological and clinical approaches, including the 2018 Nobel Prize for immune 573 
checkpoint blockade in cancer immunotherapy, no specific immune therapy treatment for 574 
GBM has been successful in phase III or randomised controlled trials due to either lack of 575 
positive response, or due to side-effects (172). Some of the clinical trials that did not show 576 
significant survival benefit include nivolumab (anti-PD-1) and ipilimubab (anti-CTLA-4) in 577 
recurrent GBM (173); nivolumab versus TMZ and radiation therapy in newly-diagnosed GBM 578 
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(174); and nivolumab in combination with TMZ and radiation therapy in newly-diagnosed 579 
GBM (175). 580 
Other emerging themes in cancer immunotherapy include inhibition of VEGF to reduce 581 
angiogenesis and vascular permeability, and cancer vaccine-based therapy such as use of DCs 582 
to activate T cells (172). The overall survival and progression-free survival was found to be 583 
increased in newly diagnosed GBM patients who received temozolamide, GM-CSF, and 584 
targeted cytomegalovirus (CMV) with DCs (176). The rationale for this being that CMV 585 
proteins have been found to be expressed in GBM but not normal brain tissue and this has 586 
been utilised to generate specific T-cell immune response to lyse GBM tumour cells (177). A 587 
follow-on randomised trial in GBM patients showed significant progression-free and overall 588 
survival in patients who received CMV-specific DC vaccination (178). Another exciting theme 589 
involves use of CART-cell therapy (chimeric-antigen receptor T-cell therapy), in which immune 590 
receptors are specifically engineered to generate an immune response when they face 591 
tumour proteins (179). A study in recurrent GBM patients, targeting a type of epidermal 592 
growth factor, using CART-cell therapy, was found to kick-start an immune response at the 593 
site of the glioma including infiltration by Treg cells (180). This small study is the first in humans 594 
and involved 10 patients with recurrent GBM. They were treated with a single peripheral dose 595 
of autologous T-cells targeted to EGFR variant III, which is found in about 30% of GBM patients 596 
and associated with poorer prognosis (181). This particular CART-cell therapy was found to 597 
be safe, the infused product reached tumour site in the brain, and also found to assert anti-598 
tumour activity by decreasing EGFR variant III expression (Figure 3).      599 
Glioma stem-like cells (GSCs) 600 
Cancer stem cell hypothesis relates to presence of cells with stem-cell like properties in the 601 
tumour microenvironment (i.e. cells that possess ability to differentiate into different cell 602 
lineage or generate new tumour or resistance to treatment) (182). The GBM 603 
microenvironment too is thought to contain such cells called as GCS that possess properties 604 
of self-renewal, pluripotency or ability to give rise to differentiated cell types, and resistance 605 
to multiple drug and radiation therapy. The presence of GSCs in GBM was first discovered by 606 
Singh et al., and since then numerous studies on GBM microenvironment have established 607 
their role in therapeutic resistance, tumour migration and invasion, capability to metastasise, 608 
as well as continued maintenance of stem cell-like state of cells (183, 184). 609 
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GSCs are considered to have the ability to escape immune response by down-regulating 610 
expression of MHC class I, thereby leading to failure of activation of cytotoxic T cells (185). 611 
One of the important mechanisms involves PD-L1 present on extracellular vesicles (lipid 612 
membrane-bound vesicles secreted by cells; also called exosomes and microvesicles) secreted 613 
by GBM cells, which block T-cell receptor by anti-CD3, thereby reducing activation and 614 
proliferation of CD4+ and CD8+ T cells  (186). GCS have also been shown to evade immune 615 
response by increasing production and infiltration of Treg cells (148), and by increasing levels 616 
of TGF-β produced by TAM, which in turn, increase levels of TGF-β which in turn down 617 
regulates MHC II and subsequent antigen processing mechanism, causing T-cell anergy (188). 618 
GSCs are known to attract TAM in vitro via chemo-attractants, CCL2 and periostin (188) and 619 
by secretion of cytokines TGF-β and CSF, which are known to polarise TAM to 620 
immunosuppressive mode (127).   621 
Myeloid-derived suppressor cells (MDSCs) in the GBM microenvironment  622 
One of the major characteristics of GBM is the abundance of Myeloid-derived suppressor cells 623 
(MDSCs) in the tumour microenvironment, which largely determines disease prognosis by 624 
immune suppressive functions.  MDSCs are the key components of innate immune system 625 
which essentially originate from the bone marrow derived cells. Significantly, infiltrations of 626 
MDSCs in GBM tumour microenvironment were markedly associated with cytotoxic T cells 627 
suppression (189,190). A recent study showed that MDSCs substantially paralyze CD4+ T cell 628 
memory functions in GBM patients (191).  Moreover, findings in GBM murine models showed 629 
that pharmacological targeting of MDSCs by Sunitinib resulted in significantly increased 630 
CD3+CD4+ T cell count in the tumour microenvironment (189,190). Moreover, the authors 631 
showed that MDSCs depletion led to improved animal survival as well as increased T cell 632 
activation in the in GBM patients’ PBMCs (189,190). Notably, GBM is characterized by a 633 
complex intra-tumour heterogeneity, which underlies a highly immunosuppressive 634 
environment and is indicative of remarkable resistance against conventional 635 
immunotherapies. Within GBM, GSCs are the major neoplastic compartment, which 636 
substantially modulates immune suppressive functions by recruitment of non-neoplastic 637 
components such as MDSCs, TAMs and Tregs in the tumour microenvironment (192-195). 638 
Previous studies have reported that GSC produce intrinsic factors such as IL-10, IL4Rα, and 639 
TGF-β to program M2 macrophages and activation of Treg cells for an effective 640 
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immunosuppressive function (188,192,194-196). In solid tumours, cell-intrinsic factors of the 641 
neoplastic compartment play a key role in recruiting TAMs and MDSCs for disease 642 
progression. For instance, recent study in GBM reported that CC chemokine CCL2 (MCP1) is 643 
the most abundant chemokine significantly correlated with poor prognosis in GBM patients 644 
(197,198). It has been shown that genetic depletion of CCL2 in the murine model, is associated 645 
with reduced infiltrations of MDSCs in the GBM microenvironment (199). The authors also 646 
showed that CCL2 depletion leads to a significant recruitment of cytotoxic T cell in the tumour 647 
microenvironment, which resulted in glioma growth suppression (199). The 648 
immunosuppressive functions of CCL2 is mediated through its binding on CCR2 and CCR4 649 
receptors, which mainly expressed on Tregs and MDSCs in GBM, respectively.  Moreover, high 650 
expression of CCL2 in the GBM microenvironment leads to infiltration of Treg cells, MDSCs, 651 
and TAMS, which subsequently is associated with poor GBM prognosis (161,197,199). 652 
Another study reported that GSCs produce macrophage migration inhibitory factor (MIF), a 653 
pro-inflammatory cytokine that recruits MDSCs for immunosuppressive functions and GSC 654 
proliferation (195). In addition, TAMs and MDSCs account for up to 50% in the immune 655 
compartment of GBM microenvironment; in particular, MDSCs are the main source of TGF-656 
and PD-L1 that induces immunosuppressive environment (191,200,201). Hence, from a 657 
clinical viewpoint, targeting the CCL2-CCR axis, MIF, and PD-L1 could potentially offer 658 
effective therapies for GBM patients.  659 
Unfortunately, the outcome of recent clinical trials of immunotherapies in GBM did not show 660 
any promising results. Therefore, personalized immunotherapy in combination with chemo-661 
radiotherapy strategies for GBM patients are currently in consideration. In line with this, 662 
findings from the most recent preclinical study confirmed that combining immuno-radiation 663 
therapy exclusively targeting MDSCs and TAMs, did result in improved survival, compared to 664 
the monotherapy cohort (194, 202).  Collectively, interfering with both cell-intrinsic factors of 665 
neoplastic compartments and immunosuppressive components (e.g. MDSCs) of the tumour 666 
microenvironment might offer an effective strategy to block GBM progression and overcome 667 






This review highlights the molecular determinants of the complex heterogeneous tumour-672 
immune environment observed in GBM and the mechanisms and interactions of various 673 
genetic pathways, transcriptional programming, immune cells and the role of the immune 674 
suppressive microenvironment in Glioblastoma. Each aspect of metabolic pathways, adaptive 675 
and immune system responses (including complement system) have a key role to play in the 676 
initiation, progression, infiltration, maintenance and suppression of tumour cells, thereby 677 
continuing to provide hope for potential effective therapies in future. The multi-dimensional 678 
interactions of glioma cells along with immune cells and other metabolic pathways add to the 679 
complexity of finding successful treatment avenues. Further research into this interplay of the 680 
immune response in GBM, along with the genomic processes underlying this, together with 681 
parallel progress in clinical trials, is required to overcome this lethal disease.   682 
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Figure legends: 1243 
Figure 1: Regulation of complement pathways in Glioblastoma: A) C1 inactivator (C1-IA), also 1244 
called C1 inhibitor (C1-Inh), binds covalently to the active site of C1r and C1s, blocking their 1245 
function.  It also dissociates C1r2C1s2 from C1, releasing the C1q. This inactivation 1246 
subsequently prevents the cleavage of C4 and C2 mediated classical pathway.  C1-IA can also 1247 
inhibit the function of MASP-1 and MASP-2 and in turn prevents cleavage of C4 and C2 of the 1248 
lectin pathway. B) Endogenous or GBM synthesized Factor H (FH) and FH-like protein 1 (FHL-1249 
1) can successfully bind to GBM cell membrane. FH is a decay accelerating factor for C3 1250 
convertase. This plasma alternative pathway regulator FH binds with C3b in the convertase, 1251 
displacing Factor Bb to inactivate the convertase. This FH-C3b also acts as a cofactor for 1252 
cleavage of C3b by Factor I (FI) to yield the inactive product iC3b. CR1 allows FI to perform the 1253 
second cleavage generating C3c and C3dg. Complement factor H related protein 5 (FHR5) 1254 
secreted from GBM also exhibits functional activity similar to factor H. FHR5 functions as a 1255 
co-factor for factor I mediated cleavage of C3b, and decay acceleration of C3 convertase, thus 1256 
inhibiting complement mediated lysis. C) The membrane bound regulators such as CD59, 1257 
CD55 and CD46 are also found to be important for resisting complement attack on GBM cells. 1258 
CD59 binds to C5b-8 complex and blocks the sites for C9 attachment, thus, preventing 1259 
polymerization of C9 and inhibition of MAC formation. CD55 inhibits the formation and 1260 
accelerates the decay of C3 and C5 convertase of alternative and classical pathway to prevent 1261 
complement activation. CD46 causes inactivation of C3b and C4b deposited on the 1262 
membrane. 1263 
Figure 2. Dissection of Mutational and Epigenetic GBM Subtype Classifications. 1264 
Glioblastoma multiforme (GBM) is a highly heterogeneous disease with distinct, recurring 1265 
molecular subtypes that differ in their associated expression profile, mutational signature and 1266 
epigenetic modifications. GBM can be classified into three main subtypes: the proneural (PN), 1267 
mesenchymal (MSC) and classical subtype. PN gliomas tend to display an expression profile 1268 
resembling oligodendrocytes, high levels of PDGFRα (due to amplifications or mutations) as 1269 
well as characteristic mutations in IDH1. The latter leads to an epigenetic CpG island 1270 
methylator phenotype (C-GIMP), which is associated with younger patients and a better 1271 
prognosis. MSC subtype tumors, on the other hand, show a high rate of NF1 mutations which, 1272 
in turn, promote NF-κB activation and, thereby, aggressiveness, invasiveness and myeloid 1273 
recruitment. This translates into a therapy resistant phenotype for MSC gliomas with poorer 1274 
survival compared to the other subtypes. The third subtype is the classical subtype, which 1275 
preserves wild-type p53 expression, but shows over-expression and/or mutation of EGFR. 1276 
Both MSC and CL tumor cells resemble (cultured) astrocytic gene expression profiles as well 1277 
as epigenetically a G-CIMP low phenotype. The distinction between G-CIMP high and low is 1278 
not only prognostically relevant (as G-CIMP high shows improved prognosis), but also 1279 
predictively. Methylation of MGMT, which is observed in G-CIMP high tumors, in conjunction 1280 
with 1p/19q deletion, has been shown to sensitize cells to TMZ treatment, leading to 1281 




Figure 3. Inflammatory Tumor Microenvironment of GBM and its Therapeutic Implications. 1284 
Illustration of the interplay of innate and adaptive immune components within the glioma 1285 
microenvironment. On the side of the innate immune system, tumour-associated 1286 
macrophages (TAMs), mainly comprised of microglia and peripheral monocytes, are attracted 1287 
by tumour cells and, in turn, release pro-inflammatory cytokines, matrix remodelers and 1288 
growth factors to aid tumorigenesis. Myeloid-derived suppressor cells (MDSCs) are also 1289 
recruited by the tumor and potently suppress anti-tumor immunity. Alternative pathway 1290 
molecules factor H (FH) and FH-like protein 1 of the complement system enhance 1291 
immunosuppression and prevent complement-mediated lysis of the tumor cells. The adaptive 1292 
immune system, on the other hand, is largely suppressed in its function through the 1293 
recruitment of regulatory T cells (Treg). These inhibit the action of cytotoxic T cells and 1294 
dendritic cells, disturbing a competent anti-tumor immune response. Tumor cells also exert 1295 
direct suppression of adaptive immunity through immune checkpoint expression, e.g. PD-L1 1296 
or CTLA-4. Therapeutically, this tumor-immune crosstalk can be targeted by inhibiting 1297 
chemoattractants of pro-tumor immune cells, such as anti-CCL2 monoclonal antibody, by 1298 
immune checkpoint inhibition, dendritic cell vaccination approaches or adoptive transfer of 1299 





Table 1: Adult (WHO Grade IV) Glioblastoma multiforme (GBM) subtypes defined by genomic, transcriptome and epigenomic markers. 
GBM phenotype Methylation status Genotypic/phenotypic abnormality   
Proneural (PN) G-CIMP+* IDH1/IDH2 mutations Ch10 deletion 
 MGMT gene promoter (high) ARTX mutation MYC 
  TP53 mutation CDKN2A/CDKN2B deletion 
 G-CIMP-* IDH1 wildtype RTKI 
  TERT promoter mutation 
PDGRFA amplification 
Ch7 insertion/chr10 deletion 
CDK4 amplification 
DLL3, OLIG2 and NKX2-2 
 
Classic (CL) Cluster M3* 





  EGFRvIII TERT promoter mutation 
  Ch7 insertion/chr10 deletion IDH1/IDH2 wildtype 
Mesenchymal (MSC) Cluster M1* NF1 mutation VEGRF2 
  TP53 mutation CD40, CD31, CD68  
  S100A1, PTPRC 
TERT promoter mutation 
CHI3L1/YKL-40, MET 
EGFR amplification (MSC subtypes) 
  Ch7 insertion/chr10 deletion ↑NF-κB driven inflammation 
Note: Neural “subtype” not use in classification as no gene clustering observed in several studies (16,20,203-205). G-CIMP: Glioma CpG island methylator phenotype; 
MGMT: O6-methylguanine-DNA methyltransferase; TERT: Telomerase reverse transcriptase; RTKI, RTKII: Receptor tyrosine kinase I and II; EGFR: Epidermal growth factor 
receptor; VEGRF2: vascular endothelial growth factor receptor 2; PTPRC: Protein Tyrosine Phosphatase Receptor Type C; S100A1: S100 Calcium Binding Protein A1; MET: 
MET-Proto-Oncogene, Receptor Tyrosine Kinase. *: Methylation cluster and G-CIMP phenotype defined by Brennan et al., 2013 (27). ↑: enhanced. Ch: Chromosome. Table 
compiled using data from the following: (14-18,25,28,55,206,207).  
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Table 2: Immune system components associated with Glioblastoma multiforme (GBM) microenvironment. 






Enhances Immunosuppression, promotes tumorigenesis, 
decreases expression of MHC class II on monocytes, promotes 
Tregs, inhibits expression of TNF-α and IFN-γ, suppresses anti-
tumor effect of immune cells 
 
(135-137) 
TGF-β TAM & GSC 
(TGFB2; Singh et 
al, 2016) 
 
Suppresses anti-tumor immune response, promotes 
tumorigenesis, blocks NK cells activity, Inhibits T-cells, promotes 
Tregs, downregulates IL-2, Inhibits NKG2D on CD8+ T-cells, 
upregulates CD133+ 
(133,134,146-148) 
IL-6 TAM Suppresses immune effector cells  (126,170) 






Enhances immunosuppression, inactivates C3b, inhibits 
activation of the complement alternative pathway 
 
(66) 
C1-IA GBM cells Enhances immunosuppression, prevents activation of the 
complement classical pathway 
(65) 
CD59 GBM cells Enhances immunosuppression, prohibits the formation of MAC, 
prevents activation of the complement pathway 
(66) 
CFH5 GBM cells Inhibits complement-mediated lysis and decay acceleration of 
C3 convertase 
(79) 
TAM    
TAM Microglia and 
macrophage/ 
monocyte 
Polarized towards M2 phenotype, enhanced 
immunosuppression, promotes tumor invasion, secretes anti-
tumor cytokines, Expresses FasL which act as an 
immunosuppressant, expresses MMPs which promote tumor 
invasion, promotes proliferation of growth factors 
 
(121,128) 
Note: IL: interleukin; TGF: transforming growth factor; CSF: colony stimulating factor; FH: factor H; C1-1A: complement 1-inactivator A; CFH5: complement factor H related 
protein 5; TAM: tumor-associated macrophage.  
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Figure 2 
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Figure 3 
 
 
